DLAT — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8168239	1.00	1/20
SCHEMBL14837010	1.00	1/20
SCHEMBL15557965	1.00	1/20
SCHEMBL15694978	1.00	1/20
Phloroglucinol (SCHEMBL30222061)	0.92	1/20
SCHEMBL98723	0.86	1/20
SCHEMBL12634392	0.86	1/20
SCHEMBL14233249	0.86	1/20
SCHEMBL14577497	0.86	1/20
SCHEMBL15694967	0.86	1/20
SCHEMBL21907266	0.86	1/20
SCHEMBL25184456	0.85	1/20
SCHEMBL7624217	0.85	1/20
SCHEMBL7871338	0.85	1/20
Methoxymethane (SCHEMBL7942622)	0.82	1/20
SCHEMBL17705185	0.81	1/20
SCHEMBL29376953	0.74	1/20
SCHEMBL7622838	0.73	1/20
SCHEMBL878771	0.73	1/20
SCHEMBL6135673	0.72	1/20

Clinical trials — most relevant to DLAT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Epidemiology of Atherosclerosis	nan	COMPLETED
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism	nan	COMPLETED
Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules	nan	COMPLETED
Supplemental Choline and Brain Development in Humans	nan	COMPLETED
Gene Expression and Inflammation in Overweight Subjects	nan	COMPLETED
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED
De Novo Lipogenesis in Severity of NAFLD	nan	COMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease	nan	NOT_YET_RECRUITING
Identification of a New Gene Involved in Hereditary Lipodystrophy	nan	COMPLETED
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DLAT binder may also engage these)

Protein	Name	Similarity
P11180	—	1.000	P11180 →
P08461	—	1.000	P08461 →
P86197	—	0.998	P86197 →
Q8BMF4	—	0.998	Q8BMF4 →
Q9N0F1	—	0.991	Q9N0F1 →
Q9D2G2	—	0.990	Q9D2G2 →
Q8BKZ9	—	0.988	Q8BKZ9 →
P11179	—	0.988	P11179 →
P22439	—	0.985	P22439 →
Q19749	—	0.983	Q19749 →
Q01205	—	0.983	Q01205 →
PDHX	Pyruvate dehydrogenase protein X component, mitochondrial	0.981	landscape →
DLST	Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial	0.981	landscape →
Q90512	—	0.981	Q90512 →
P53395	—	0.981	P53395 →
Q0WQF7	—	0.981	Q0WQF7 →
O59816	—	0.980	O59816 →
P36413	—	0.980	P36413 →
P20285	—	0.977	P20285 →
Q8RWN9	—	0.976	Q8RWN9 →
Q5M729	—	0.976	Q5M729 →
Q9FLQ4	—	0.976	Q9FLQ4 →
P11181	—	0.974	P11181 →
O94681	—	0.974	O94681 →
Q23571	—	0.974	Q23571 →
Q8H107	—	0.973	Q8H107 →
A0A0D2Y5A7	—	0.973	A0A0D2Y5A7 →
P12695	—	0.972	P12695 →
P35489	—	0.972	P35489 →
P19262	—	0.971	P19262 →